Literature DB >> 1345344

Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin.

L Bertilsson1, Y Q Lou, Y L Du, Y Liu, T Y Kuang, X M Liao, K Y Wang, J Reviriego, L Iselius, F Sjöqvist.   

Abstract

The frequency of poor metabolizers of debrisoquin was low and similar in four different native Chinese nationalities. In a total sample of 695 Chinese subjects, only seven (1.01%) had a urinary ratio between debrisoquin and 4-hydroxydebrisoquin greater than 12.6, which is the antimode between poor metabolizers and extensive metabolizers in white populations. This is significantly lower than the 6.82% found in 1011 white Swedish healthy subjects (p less than 0.0001). Admixture analysis indicated the occurrence of two distributions within extensive metabolizers among both Chinese and white subjects. The mean of the distribution of metabolic ratios among Chinese extensive metabolizers was shifted toward higher values compared with Swedish extensive metabolizers (p less than 0.01). The frequency of poor metabolizers of S-mephenytoin was higher in 137 Chinese (14.6%) than in 488 Swedish (3.3%) subjects (p less than 0.0001). Our findings imply that drugs metabolized by these two polymorphic hydroxylases should be prescribed in different dosages to Chinese and white subjects.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1345344     DOI: 10.1038/clpt.1992.38

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  79 in total

1.  Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.

Authors:  L Bathum; E Skjelbo; T K Mutabingwa; H Madsen; M Hørder; K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

Review 2.  Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.

Authors:  Leif Bertilsson; Marja-Liisa Dahl; Per Dalén; Ayman Al-Shurbaji
Journal:  Br J Clin Pharmacol       Date:  2002-02       Impact factor: 4.335

3.  Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients.

Authors:  H K Roh; J Y Chung; D Y Oh; C S Park; J O Svensson; M L Dahl; L Bertilsson
Journal:  Br J Clin Pharmacol       Date:  2001-09       Impact factor: 4.335

4.  Effect of CYP2D6*10 on pharmacokinetic variability of routinely administered metoprolol in middle-aged and elderly Japanese patients.

Authors:  Masato Taguchi; Takashi Nozawa; Tomoki Kameyama; Hiroshi Inoue; Chihiro Takesono; Akiko Mizukami; Yukiya Hashimoto
Journal:  Eur J Clin Pharmacol       Date:  2003-08-12       Impact factor: 2.953

5.  CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking.

Authors:  Margareta Ramsjö; Eleni Aklillu; Lilleba Bohman; Magnus Ingelman-Sundberg; Hyung-Keun Roh; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2010-05-25       Impact factor: 2.953

Review 6.  Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.

Authors:  I Fricke-Galindo; C Céspedes-Garro; F Rodrigues-Soares; M E G Naranjo; Á Delgado; F de Andrés; M López-López; E Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

7.  Terbinafine-associated inhibition of dextromethorphan metabolism in Chinese subjects.

Authors:  W M Cai; B Chen; S S Ling; Y D Zhang
Journal:  Br J Clin Pharmacol       Date:  2001-01       Impact factor: 4.335

Review 8.  Polymorphic cytochromes P450 and drugs used in psychiatry.

Authors:  R T Coutts; L J Urichuk
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

9.  Cytochrome P4502D6 genotype does not determine response to clozapine.

Authors:  M J Arranz; E Dawson; S Shaikh; P Sham; T Sharma; K Aitchison; M A Crocq; M Gill; R Kerwin; D A Collier
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

10.  Rectal ropivacaine is absorbed proportionally to the dose, with low intraindividual variability.

Authors:  Eva Arlander; Jan Sjövall; Jörgen Sörstad; Carina Norsten-Höög; Lars L Gustafsson
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.